[Expression and clinical significance of CDC6 and hMSH2 in cervical carcinoma].
To detect the expression of CDC6 and hMSH2 in cervical carcinoma, explore the correlation with clinical significance and pelvic lymph node metastases. SP immunohistochemistry technique was used to detect the expression of CDC6 and hMSH2 in specimens of 70 cervical carcinoma, and 14 normal cervix. Correlation between the expression of CDC6, hMSH2 and the clinicopathologic factors of cervical carcinoma were statistically analyzed. The rates of positive expression of CDC6 and hMSH2 were 70.0%, 54.3% in cervical carcinoma, and significantly higher than those in normal cervix (P=0.000, 0.006). The CDC6 expression rate was related to pathological subtype, FIGO stage, histological tumor grade, pelvic lymph node metastases (P<0.05). The hMSH2 expression rate was related to pathological subtype, FIGO stage and pelvic lymph node metastases (P<0.05), but did not associate with histological tumor grade. The expression of CDC6 was positively correlated with hMSH2 in cervical cancer (r(s)=0.338, P=0.004), meanwhile it was not correlated with hMSH2 in 19 patients with pelvic lymph node metastases. CDC6 and hMSH2 play an important role in the invasion and metastasis of cervical carcinoma. CDC6 and hMSH2 may be useful for predicting prognosis of cervical carcinoma.